Lyle Wesley Baker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lyle Wesley Baker has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Fouad T. Chebib
Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida
4 shared publications - Ivan Porter Iii
Division of Nephrology and Hypertension Mayo Clinic Jacksonville Florida USA
3 shared publications - Michael A. Mao
Division of Nephrology and Hypertension Mayo Clinic Jacksonville Florida USA
3 shared publications - Nabeel Aslam
Division of Nephrology & Hypertension, Mayo Clinic, Jacksonville, Florida, USA
3 shared publications Sam T. Albadri
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida
3 shared publications- Abdul Hamid Borghol
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, Florida
2 shared publications
Latest Publications
- 29 October 2026
- Published by Elsevier in Mayo Clinic Proceedings
51-Year-Old Woman with Marked Blood Pressure Lability
- 29 October 2026
- Published by Elsevier in Mayo Clinic Proceedings
51-Year-Old Woman with Marked Blood Pressure Lability
- Open Access
- 10 September 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (9) , e70360
Virtual Reality Reduces Office Blood Pressure and Anxiety in Patients Undergoing Ambulatory Blood Pressure Monitoring: Enhanced Response among Those With a Pronounced White Coat Response
Office blood pressure (OBP) may be transiently elevated during clinical encounters because of situational anxiety and stress‐related physiologic arousal, contributing to diagnostic uncertainty and potential overtreatment. Virtual reality (VR)‐based relaxation can reduce stress‐related physiologic responses, but its effects on OBP and potential role in mitigating the white coat response among patients undergoing ambulatory blood pressure monitoring (ABPM) have not been evaluated. We conducted a prospective, single‐arm, pre‐post study among adults undergoing ABPM in a tertiary hypertension clinic. Participants completed paired OBP measurements and validated anxiety assessments before and after a brief immersive VR relaxation experience. ABPM results were used to classify predefined blood pressure subgroups. Seventy‐eight participants completed the study (mean age 62 ± 15 years; 47% female). Across the cohort, systolic OBP decreased by 6.1 mmHg (95% CI, −7.6 to −4.6; p < 0.001) and diastolic OBP by 1.4 mmHg ( p = 0.002) following VR exposure. Participants with a pronounced white coat response, prespecified as an office‐to‐daytime ambulatory systolic BP difference ≥15 mmHg, experienced the greatest systolic BP reduction (−12.2 mmHg; p < 0.001), compared with smaller or nonsignificant changes in other subgroups (between‐group p = 0.005). Following VR exposure, 32.1% of participants were reclassified to a lower OBP category. Anxiety scores decreased significantly, and no adverse effects were reported. A brief VR relaxation intervention was associated with significant reductions in OBP and anxiety, particularly among participants with a pronounced white coat response, supporting its potential as an adjunct for improving OBP assessment in hypertension clinics. Clinical Trial Registration: Clinical Trials. gov Identifier: NCT06960057
- 10 September 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (9) , e70360
Open AccessVirtual Reality Reduces Office Blood Pressure and Anxiety in Patients Undergoing Ambulatory Blood Pressure Monitoring: Enhanced Response among Those With a Pronounced White Coat Response
Office blood pressure (OBP) may be transiently elevated during clinical encounters because of situational anxiety and stress‐related physiologic arousal, contributing to diagnostic uncertainty and potential overtreatment. Virtual reality (VR)‐based relaxation can reduce stress‐related physiologic responses, but its effects on OBP and potential role in mitigating the white coat response among patients undergoing ambulatory blood pressure monitoring (ABPM) have not been evaluated. We conducted a prospective, single‐arm, pre‐post study among adults undergoing ABPM in a tertiary hypertension clinic. Participants completed paired OBP measurements and validated anxiety assessments before and after a brief immersive VR relaxation experience. ABPM results were used to classify predefined blood pressure subgroups. Seventy‐eight participants completed the study (mean age 62 ± 15 years; 47% female). Across the cohort, systolic OBP decreased by 6.1 mmHg (95% CI, −7.6 to −4.6; p < 0.001) and diastolic OBP by 1.4 mmHg ( p = 0.002) following VR exposure. Participants with a pronounced white coat response, prespecified as an office‐to‐daytime ambulatory systolic BP difference ≥15 mmHg, experienced the greatest systolic BP reduction (−12.2 mmHg; p < 0.001), compared with smaller or nonsignificant changes in other subgroups (between‐group p = 0.005). Following VR exposure, 32.1% of participants were reclassified to a lower OBP category. Anxiety scores decreased significantly, and no adverse effects were reported. A brief VR relaxation intervention was associated with significant reductions in OBP and anxiety, particularly among participants with a pronounced white coat response, supporting its potential as an adjunct for improving OBP assessment in hypertension clinics. Clinical Trial Registration: Clinical Trials. gov Identifier: NCT06960057
- 21 July 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (2) , A11-A14
An Uncommon Root Cause of Severe Hypokalemia and Hypertension: A Quiz
- 21 July 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (2) , A11-A14
An Uncommon Root Cause of Severe Hypokalemia and Hypertension: A Quiz
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 5 (2)
Silica Nephrolithiasis From Commonly Used Over-the-Counter Vitamins and Supplements: A Case Report
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 5 (2)
Silica Nephrolithiasis From Commonly Used Over-the-Counter Vitamins and Supplements: A Case Report
- Open Access
- 2 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (12) , 2057-2060
Before the Pressure Rises
- 2 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (12) , 2057-2060
Open AccessBefore the Pressure Rises
- 23 October 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 143, 106557
Contemporary management of advanced chronic kidney disease: An evidence-based review
- 23 October 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 143, 106557
Contemporary management of advanced chronic kidney disease: An evidence-based review
- Open Access
- 7 July 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1618-1631
Pain Management in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder. It is primarily caused by pathogenic variants in the PKD1 or PKD2 genes. This leads to the development of numerous kidney cysts, which can result in kidney enlargement and progression to kidney failure. Pain is a common symptom in ADPKD and can negatively affect quality of life (QOL). This pain is often due to the continuous growth of kidney and liver cysts or associated cystic complications. We present a case of a 29-year-old woman with ADPKD who experienced chronic, refractory right-sided flank pain that significantly affected her QOL. Her pain persisted despite taking daily multimodal analgesics and undergoing multiple invasive interventions. She had an unusual asymmetric disease with the right kidney accounting for only 24% of her kidney function. After exhausting all other pain control strategies, she underwent right nephrectomy and partial hepatectomy, which led to substantial improvement in pain and QOL. This review describes the causes, manifestations, and management strategies for abdominal and/or flank pain in ADPKD, including a practical stepwise algorithm to guide clinicians in managing pain and improve QOL of patients with ADPKD. Pain in ADPKD can either be acute or chronic and can lead to significant physical and psychologic distress. Effective pain management in ADPKD requires a multidisciplinary approach, incorporating both nonpharmacologic and pharmacologic interventions such as gabapentin or tolvaptan in select cases. Interventions considered in ADPKD pain control include cyst aspiration with sclerotherapy, celiac plexus blockade, spinal cord stimulation, renal denervation, or nephrectomy.
- 7 July 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1618-1631
Open AccessPain Management in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder. It is primarily caused by pathogenic variants in the PKD1 or PKD2 genes. This leads to the development of numerous kidney cysts, which can result in kidney enlargement and progression to kidney failure. Pain is a common symptom in ADPKD and can negatively affect quality of life (QOL). This pain is often due to the continuous growth of kidney and liver cysts or associated cystic complications. We present a case of a 29-year-old woman with ADPKD who experienced chronic, refractory right-sided flank pain that significantly affected her QOL. Her pain persisted despite taking daily multimodal analgesics and undergoing multiple invasive interventions. She had an unusual asymmetric disease with the right kidney accounting for only 24% of her kidney function. After exhausting all other pain control strategies, she underwent right nephrectomy and partial hepatectomy, which led to substantial improvement in pain and QOL. This review describes the causes, manifestations, and management strategies for abdominal and/or flank pain in ADPKD, including a practical stepwise algorithm to guide clinicians in managing pain and improve QOL of patients with ADPKD. Pain in ADPKD can either be acute or chronic and can lead to significant physical and psychologic distress. Effective pain management in ADPKD requires a multidisciplinary approach, incorporating both nonpharmacologic and pharmacologic interventions such as gabapentin or tolvaptan in select cases. Interventions considered in ADPKD pain control include cyst aspiration with sclerotherapy, celiac plexus blockade, spinal cord stimulation, renal denervation, or nephrectomy.
- Open Access
- 7 July 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (11) , 1918-1927
Multicenter Insights into Peritoneal Dialysis for Autosomal Dominant Polycystic Kidney Disease
Key Points: This study demonstrates that peritoneal dialysis is a safe and feasible option for patients with autosomal dominant polycystic kidney disease, even with high cystic organ volumes. Larger organ volumes, including height-adjusted cumulative kidney and liver volume, were not associated with increased peritoneal dialysis–related complications. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and the fourth leading cause of kidney failure. Peritoneal dialysis (PD), preferred for its home-based convenience and cost-effectiveness, is often underutilized in ADPKD because of concerns over enlarged kidneys and heightened risk of complications. Methods: This retrospective cohort study used data from the Mayo Clinic Polycystic Kidney Disease Database to evaluate individuals with ADPKD undergoing PD. We analyzed demographics, clinical parameters, and PD-related parameters. Complications were correlated with kidney and liver volumes derived from pre-kidney failure imaging. Results: A total of 155 individuals with ADPKD on PD were included, of whom 45.1% were male. The mean age at PD initiation was 54.3±12.8 years, and the mean body mass index was 28.0±7.0 kg/m 2 . The median duration of PD was 24.3 months (interquartile range [IQR], 10.7–43.1), with 21.9% transitioning to hemodialysis. The most common complications were abdominal hernias (30.3%) and peritonitis (23.9%), with a peritonitis rate of 0.11 episodes per patient-year. Imaging analyses performed on a subset of 50 patients showed a median height-adjusted total kidney liver volume of 2731.9 ml/m (IQR, 2102.5–3131.1) and a median height-adjusted total kidney volume of 1303.5 ml/m (IQR, 733.1–1829.4). Kaplan–Meier analysis demonstrated no differences in complications rates on the basis of height-adjusted total kidney liver volume or height-adjusted total kidney volume (above versus below median values) or body mass index categories. Multivariate Cox regression analysis revealed that higher height-adjusted cumulative organ volume was associated with a lower risk of PD-related complications (hazard ratio=0.56, P = 0.026). Conclusions: PD is a safe and feasible treatment option for patients with ADPKD, with no increased risk of PD-related complications associated with larger height-adjusted cumulative organ volumes. Infectious complication rates in this cohort were within International Society of Peritoneal Dialysis guideline thresholds, further supporting the safety of PD in this population.
- 7 July 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (11) , 1918-1927
Open AccessMulticenter Insights into Peritoneal Dialysis for Autosomal Dominant Polycystic Kidney Disease
Key Points: This study demonstrates that peritoneal dialysis is a safe and feasible option for patients with autosomal dominant polycystic kidney disease, even with high cystic organ volumes. Larger organ volumes, including height-adjusted cumulative kidney and liver volume, were not associated with increased peritoneal dialysis–related complications. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and the fourth leading cause of kidney failure. Peritoneal dialysis (PD), preferred for its home-based convenience and cost-effectiveness, is often underutilized in ADPKD because of concerns over enlarged kidneys and heightened risk of complications. Methods: This retrospective cohort study used data from the Mayo Clinic Polycystic Kidney Disease Database to evaluate individuals with ADPKD undergoing PD. We analyzed demographics, clinical parameters, and PD-related parameters. Complications were correlated with kidney and liver volumes derived from pre-kidney failure imaging. Results: A total of 155 individuals with ADPKD on PD were included, of whom 45.1% were male. The mean age at PD initiation was 54.3±12.8 years, and the mean body mass index was 28.0±7.0 kg/m 2 . The median duration of PD was 24.3 months (interquartile range [IQR], 10.7–43.1), with 21.9% transitioning to hemodialysis. The most common complications were abdominal hernias (30.3%) and peritonitis (23.9%), with a peritonitis rate of 0.11 episodes per patient-year. Imaging analyses performed on a subset of 50 patients showed a median height-adjusted total kidney liver volume of 2731.9 ml/m (IQR, 2102.5–3131.1) and a median height-adjusted total kidney volume of 1303.5 ml/m (IQR, 733.1–1829.4). Kaplan–Meier analysis demonstrated no differences in complications rates on the basis of height-adjusted total kidney liver volume or height-adjusted total kidney volume (above versus below median values) or body mass index categories. Multivariate Cox regression analysis revealed that higher height-adjusted cumulative organ volume was associated with a lower risk of PD-related complications (hazard ratio=0.56, P = 0.026). Conclusions: PD is a safe and feasible treatment option for patients with ADPKD, with no increased risk of PD-related complications associated with larger height-adjusted cumulative organ volumes. Infectious complication rates in this cohort were within International Society of Peritoneal Dialysis guideline thresholds, further supporting the safety of PD in this population.
- 19 June 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 86 (1) , A13-A16
Peripheral Neuropathy Presenting With Hypereosinophilia: A Quiz
- 19 June 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 86 (1) , A13-A16
Peripheral Neuropathy Presenting With Hypereosinophilia: A Quiz
- Open Access
- 16 May 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (7) , 101027
Kidney Outcomes in Patients With Advanced Heart Failure Treated With Ventricular Assist Devices
- 16 May 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (7) , 101027
Open AccessKidney Outcomes in Patients With Advanced Heart Failure Treated With Ventricular Assist Devices